Table 2.
Activity of different antibiotics against selected Gram-positive bacteria
| Antibiotic |
MSSA |
MRSA |
VRSA |
VRE |
References |
|||
|---|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | MIC50 | MIC90 | MIC range | MIC50 | MIC90 | ||
| Vancomycin | 1 | 1 | 1 | 1 | 32–1024 | >64 | >64 | Zeckel et al 2000; Sader et al 2008b; Sievert et al 2008 |
| Linezolid | 2 | 2 | 2 | 2 | 2–4 | 1 | 2 | Deshpande et al 2007; Sader et al 2008b; Sievert et al 2008 |
| Daptomycin | 0.25 | 0.5 | 0.25 | 0.5 | ≤0.5–2 | 2 | 4 | Sader et al 2007, 2008b; Sievert et al 2008 |
| Tigecycline | 0.12 | 0.25 | 0.12 | 0.25 | 0.12 | 0.03 | 0.06 | Bozdogan et al 2003; Hoban et al 2005; Gales et al 2008 |
| Ceftobiprole | 0.25 | 0.5 | 1 | 2 | 1 | 4 | 8 | Swenson and Tenover, 2002; Bozdogan et al 2003; Jones, 2007; Pillar et al 2008 |
| Ceftaroline | 0.25 | 0.25 | 1 | 2 | Not reported | 16 | >32 | Sader et al 2005 |
| Oritavancin | 1 | 2 | 1 | 2 | 0.25b | 1 | 2 | Zeckel et al 2000; Bozdogan et al 2003 |
| Dalbavancin | 0.06 | 0.06 | 0.06 | 0.06 | 0.5b | 4 | 32 | Bozdogan et al 2003; Streit et al 2004; Jones et al 2006 |
| Telavancin | 0.5 | 0.5 | 0.25 | 0.5 | 2–4c | 2 | 4 | King et al 2004; Leuthner et al 2006 |
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; VRSA, vancomycin-resistant S. aureus; VRE, vancomycin-resistant Enterococcus; MIC50, minimal inhibitory concentration for 50% of tested strains; MIC90, minimal inhibitory concentration for 90% of tested strains; MIC, minimal inhibitory concentration (μg/ml).